Thomas Smith
Stock Analyst at Leerink Partners
(0.98)
# 3,439
Out of 4,670 analysts
69
Total ratings
25%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $3.80 | +84.21% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $9.46 | +206.55% | 1 | Jul 23, 2024 | |
| QTTB Q32 Bio | Initiates: Outperform | $54 | $24.55 | +119.96% | 1 | May 21, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $18.87 | +106.68% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $4.76 | +446.22% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $1.08 | +825.93% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $8.78 | +127.79% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $605.92 | -28.21% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $64.96 | -44.58% | 1 | Feb 28, 2023 | |
| EQ Equillium | Maintains: Outperform | $12 → $7 | $0.71 | +884.53% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.00 | +600.00% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $26.87 | -21.85% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $20.20 | +122.77% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $2.91 | +106.19% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $6.84 | -12.28% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.10 | +354.55% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $54.32 | -68.70% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $27.02 | +136.86% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $22.55 | +210.42% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $8.76 | +231.05% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $4.01 | +548.38% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $0.88 | +1,268.93% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $52.59 | -77.18% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.20 | +138.10% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $5.62 | +7,017.44% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $55.92 | +43.06% | 2 | Dec 8, 2020 |
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $3.80
Upside: +84.21%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $9.46
Upside: +206.55%
Q32 Bio
May 21, 2024
Initiates: Outperform
Price Target: $54
Current: $24.55
Upside: +119.96%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $18.87
Upside: +106.68%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $4.76
Upside: +446.22%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $1.08
Upside: +825.93%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $8.78
Upside: +127.79%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $605.92
Upside: -28.21%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $64.96
Upside: -44.58%
Equillium
Feb 8, 2023
Maintains: Outperform
Price Target: $12 → $7
Current: $0.71
Upside: +884.53%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.00
Upside: +600.00%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $26.87
Upside: -21.85%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $20.20
Upside: +122.77%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $2.91
Upside: +106.19%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $6.84
Upside: -12.28%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.10
Upside: +354.55%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $54.32
Upside: -68.70%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $27.02
Upside: +136.86%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $22.55
Upside: +210.42%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $8.76
Upside: +231.05%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $4.01
Upside: +548.38%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $0.88
Upside: +1,268.93%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $52.59
Upside: -77.18%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.20
Upside: +138.10%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $5.62
Upside: +7,017.44%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $55.92
Upside: +43.06%